Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Opioid Receptor

  • Vladana VukojevićEmail author
  • Yu Ming
  • Tijana Jovanović-Talisman
  • Lars Terenius
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_596


From http://www.genome.jp/kegg/genes.html

 μ-opioid receptor (MOP): OPRM1, KIAA0403, LMOR, MOR, MOR1, OPRM

 δ-opioid receptor (DOP): OPRD1, OPRD

 κ-opioid receptor (KOP): OPRK1, KOR, OPRK

 Nociceptin opioid receptor (NOP): OPRL1, KOR-3, MGC34578, NOCIR, OOR, ORL1

Historical Background

The existence of opioid receptors (OR) was postulated in 1954 (Beckett and Casy 1954), at a time when evidence for specific drug-responsive substances was evasive and the concept of biochemical receptors was still in its infancy. Unequivocal confirmation of specific binding sites for opioids in the brain was first reported in 1973 (Pert and Snyder 1973; Simon et al. 1973; Terenius 1973). This breakthrough was shortly followed by evidence that opioid ligands bind specifically to different anatomical locations and show different pharmacological activity, suggesting that several types of opioid receptors exist (Martin et al. 1976; Lord et al. 1977). Based on extensive pharmacological and animal...

This is a preview of subscription content, log in to check access.


  1. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci. 2007;8:128–40.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65:135–44.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Baker A, Saulière A, Dumas F, Millot C, Mazères S, Lopez A, Salomé L. Functional membrane diffusion of G-protein coupled receptors. Eur Biophys J. 2007;36:849–86.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Beckett AH, Casy AF. Synthetic analgesics: stereochemical considerations. J Pharm Pharmacol. 1954;6:986–1001.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Bodnar RJ. Endogenous opiates and behavior. Peptides. 2010;31:2325–59.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Dean R, Bilsky EJ, Stevens Negus S (Eds). Opiate receptors and antagonists. From bench to clinic. New York: Humana Press; 2009. p. 201–26.Google Scholar
  7. Dreborg S, Sundström G, Larsson TA, Larhammar D. Evolution of vertebrate opioid receptors. Proc Natl Acad Sci USA. 2008;105:15487–92.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Evans CJ, Keith Jr DE, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science. 1992;258:1952–5.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Fortin JP, Ci L, Schroeder J, Goldstein C, Montefusco MC, Peter I, Reis SE, Huggins GS, Beinborn M, Kopin AS. The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs. Mol Pharmacol. 2010;78:837–45.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, Weis WI, Kobilka BK. Structure of the δ-opioid receptor bound to naltrindole. Nature. 2012;485(7398):400–4.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Halls ML, Yeatman HR, Nowell CJ, Thompson GL, Gondin AB, Civciristov S, Bunnett NW, Lambert NA, Poole DP, Canals M. Plasma membrane localization of the μ-opioid receptor controls spatiotemporal signaling. Sci. Signal. 2016;9(414):ra16.  https://doi.org/10.1126/scisignal.aac9177.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Hanyaloglu AC, von Zastrow M. Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol. 2008;48:537–68.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Huang P, Chen C, Xu W, Yoon SI, Unterwald EM, Pintar JE, Wang Y, Chong PL, Liu-Chen LY. Brain region-specific N-glycosylation and lipid rafts association of the rat mu opioid receptor. Biochem Biophys Res Commun. 2008;365:82–8.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL, Kato HE, Livingston KE, Thorsen TS, Kling RC, Granier S, Gmeiner P, Husbands SM, Traynor JR, Weis WI, Steyaert J, Dror RO, Kobilka BK. Structural insights into μ-opioid receptor activation. Nature. 2015;524(7565):315–21.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Jorand R, Biswas S, Wakefield DL, Tobin SJ, Golfetto O, Hilton K, Ko M, Ramos JW, Small AR, Chu P, Singh G, Jovanovic-Talisman T. Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Mol Biol Cell. 2016;27:3659–72.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Kane BE, Svensson B, Ferguson DM. Molecular recognition of opioid receptor ligands. AAPS J. 2006;8:E126–37.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA. 1992;89:12048–52.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Levac BA, O’Dowd BF, George SR. Oligomerization of opioid receptors: generation of novel signaling units. Curr Opin Pharmacol. 2002;2:76–81.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977;267:495–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, Pardo L, Weis WI, Kobilka BK, Granier S. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature. 2012;485(7398):321–6.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hübner H, Huang XP, Sassano MF, Giguère PM, Löber S, Duan D, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016;537(7619):185–90.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197:517–32.PubMedPubMedCentralGoogle Scholar
  23. Meunier J-C, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour J-L, Guillemot JC, Ferrara P, Monsarrat B. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995;377:532–5.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Milligan G. The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. Curr Opin Pharmacol. 2010;10:23–9.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Pan YX, Xu J, Mahurter L, Xu M, Gilbert AK, Pasternak GW. Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun. 2003;301:1057–61.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science. 1973;179:1011–4.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ, Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995;270:792–4.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Simon EJ, Hiller JM, Edelman I. Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. Proc Natl Acad Sci USA. 1973;70:1947–9.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Sounier R, Mas C, Steyaert J, Laeremans T, Manglik A, Huang W, Kobilka BK, Déméné H, Granier S. Propagation of conformational changes during μ-opioid receptor activation. Nature. 2015;524(7565):375–8.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Terenius L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacol Toxicol (Copenh). 1973;32:317–20.CrossRefGoogle Scholar
  31. Thompson AA, Liu W, Chun E, Katritch V, Wu H, Vardy E, Huang XP, Trapella C, Guerrini R, Calo G, Roth BL, Cherezov V, Stevens RC. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature. 2012;485(7398):395–9.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Tobin SJ, Cacao EE, Hong DW, Terenius L, Vukojevic V, Jovanovic-Talisman T. Nanoscale effects of ethanol and naltrexone on protein organization in the plasma membrane studied by photoactivated localization microscopy (PALM). PLoS One. 2014;9(2):e87225.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Vukojević V, Ming Y, D’Addario C, Hansen M, Langel U, Schulz R, Johansson B, Rigler R, Terenius L. Mu-opioid receptor activation in live cells. FASEB J. 2008;22:3537–48.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, Liu W, Thompson AA, Huang XP, Carroll FI, Mascarella SW, Westkaemper RB, Mosier PD, Roth BL, Cherezov V, Stevens RC. Structure of the human κ-opioid receptor in complex with JDTic. Nature. 2012;485(7398):327–32.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Vladana Vukojević
    • 1
    Email author
  • Yu Ming
    • 1
  • Tijana Jovanović-Talisman
    • 2
  • Lars Terenius
    • 1
  1. 1.Center for Molecular Medicine, Department of Clinical NeuroscienceKarolinska InstituteStockholmSweden
  2. 2.Department of Molecular MedicineBeckman Research Institute of the City of Hope Comprehensive Cancer CenterDuarteUSA